According to the Zhitong Finance App, Cinda Biotech (01801.HK) announced that in the first half of 2026, the company's product revenue exceeded RMB 8.2 billion, an increase of more than 55% over the previous year. Among them, the company's product revenue in the second quarter exceeded RMB 4.3 billion, an increase of about 60% over the previous year. This strong performance fully reflects the continued effectiveness of the company's “two-wheel drive” strategy. The comprehensive product line has maintained strong growth, and core products such as Xinermei® (Maxidopeptide Injection), Cinpirac® (Tolexizumab Injection), and Cinbimin® (Tetuumab N01 Injection) have performed well and have become an important driving force for revenue growth. At the same time, the company's leading edge in the field of oncology continues to stabilize. The market penetration rate of the five new tyrosine kinase inhibitors (TKIs) included in the National Health Insurance Catalogue (NRDL) continues to increase, and revenue volume accelerates. Furthermore, the company successfully expanded its strategy into the commercialization field of treatment of breast cancer, and reached a commercial cooperation with Eli Lilly® (abecilil tablets) in mainland China, laying a solid foundation for the company's subsequent breast cancer pipeline development and market expansion.

According to the Zhitong Finance App, Cinda Biotech (01801.HK) announced that in the first half of 2026, the company's product revenue exceeded RMB 8.2 billion, an increase of more than 55% over the previous year. Among them, the company's product revenue in the second quarter exceeded RMB 4.3 billion, an increase of about 60% over the previous year. This strong performance fully reflects the continued effectiveness of the company's “two-wheel drive” strategy. The comprehensive product line has maintained strong growth, and core products such as Xinermei® (Maxidopeptide Injection), Cinpirac® (Tolexizumab Injection), and Cinbimin® (Tetuumab N01 Injection) have performed well and have become an important driving force for revenue growth. At the same time, the company's leading edge in the field of oncology continues to stabilize. The market penetration rate of the five new tyrosine kinase inhibitors (TKIs) included in the National Health Insurance Catalogue (NRDL) continues to increase, and revenue volume accelerates. Furthermore, the company successfully expanded its strategy into the commercialization field of treatment of breast cancer, and reached a commercial cooperation with Eli Lilly® (abecilil tablets) in mainland China, laying a solid foundation for the company's subsequent breast cancer pipeline development and market expansion.